hydroxyurea has been researched along with Malignant Melanoma in 73 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388), melphalan, and hydroxyurea were evaluated in a randomized clinical trial in which 35 patients with disseminated malignant melanoma were treated." | 9.03 | Clinical evaluation of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxam-ide (NSC-45388), melphalan (NSC-8806), and hydroxyurea (NSC-32065) in the treatment of disseminated malignant melanoma. ( Ahmann, DL; Bisel, HF; Hahn, RG, 1972) |
| "Dacarbazine (DTIC) is a DNA-methylating drug used in the treatment of malignant melanoma." | 7.69 | Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. ( Ganesan, TS; Harris, AL; Kyrtopoulos, SA; Mitchell, K; Philip, PA; Salisbury, A; Souliotis, VL; Tates, AD; van Delft, JH, 1996) |
| "We have studied chemotherapy enhancement by the combination of the biscoclaurine alkaloid, Cepharanthine (Ceph), using the inhibition of colony forming efficiency (CFE) of B16 melanoma cells in vitro." | 7.68 | [Enhancement of the effects of anticancer agents on B16 melanoma cells by combination with cepharanthine--II. Antimetabolite, alkylating agent, nitrosourea]. ( Kubota, K; Kubota, R; Yamada, S, 1992) |
| "In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma." | 7.67 | Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma. ( Amato, DA; Ash, A; Borden, EC; Bruckner, H; Creech, RH; Cunningham, TJ; Falkson, G; Guerry, D; Savlov, ED, 1987) |
| "The effect of novobiocin on the formation of DNA replication intermediates in human melanoma cells was investigated." | 7.66 | Formation of a new DNA replication intermediate in novobiocin-treated human melanoma cells. ( Lönn, U, 1982) |
| "Hydroxyurea (HU) is a ribonucleotide reductase inhibitor which blocks DNA excision-repair by the depletion of intracellular ribonucleotides." | 6.67 | A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. ( Carmichael, J; Ganesan, TA; Harris, AL; Philip, PA; Tonkin, K, 1994) |
| "Hydroxyurea (HU) is used to treat melanoma, and miRNA expression is altered after HU treatment in B16 melanoma cells." | 5.62 | Hydroxyurea regulates the development and survival of B16 Melanoma Cells by upregulating MiR-7013-3p. ( Gao, Y; Han, DX; Huang, YJ; Jiang, H; Wang, CJ; Wang, WH; Yuan, B; Zhang, JB; Zheng, Y, 2021) |
| "In 1975, the Southwest Oncology Group initiated an adjuvant study in localized malignant melanoma testing the value of aggressive chemotherapy using carmustine, hydroxyurea, and dacarbazine versus a control arm." | 5.06 | Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study. ( Balcerzak, SP; Costanzi, JH; Dixon, D; Fabian, CJ; Maloney, T; Neidhart, J; Neilan, B; O'Bryan, RM; Quagliana, J; Tranum, BL, 1987) |
| "Thirty-three patients with malignant melanoma and regional lymph node metastases who underwent lymph node dissection were additionally given polychemotherapy with carmustine, hydroxycarbamide and dacarbazine immediately before surgery and up to five times postoperatively." | 5.06 | [Adjuvant chemotherapy in addition to radical surgical treatment of regional lymph node metastases in malignant melanoma]. ( Aragon, V; Bröcker, EB; Bünte, H; Czarnetzki, BM; Krieg, V; Macher, E, 1986) |
| "5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388), melphalan, and hydroxyurea were evaluated in a randomized clinical trial in which 35 patients with disseminated malignant melanoma were treated." | 5.03 | Clinical evaluation of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxam-ide (NSC-45388), melphalan (NSC-8806), and hydroxyurea (NSC-32065) in the treatment of disseminated malignant melanoma. ( Ahmann, DL; Bisel, HF; Hahn, RG, 1972) |
| "F10 mouse melanoma cells were partially synchronized with hydroxyurea, thymidine, or by mitotic shake-off." | 3.76 | The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis. ( Annels, NE; Harrington, KJ; Heinemann, L; Melcher, A; Pandha, HS; Prestwich, R; Simpson, GR; Vile, R, 2010) |
| " The direct cytotoxicity of piroxicam indomethacin, and aspirin against 4 canine tumor cell lines (transitional cell carcinoma, squamous cell carcinoma, melanoma, and soft tissue sarcoma) was determined in short-term growth rate assays and in clonogenic assays." | 3.69 | Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. ( Chan, TC; Knapp, DW; Kuczek, T; Park, B; Reagan, WJ, 1995) |
| "Dacarbazine (DTIC) is a DNA-methylating drug used in the treatment of malignant melanoma." | 3.69 | Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. ( Ganesan, TS; Harris, AL; Kyrtopoulos, SA; Mitchell, K; Philip, PA; Salisbury, A; Souliotis, VL; Tates, AD; van Delft, JH, 1996) |
| "We have studied chemotherapy enhancement by the combination of the biscoclaurine alkaloid, Cepharanthine (Ceph), using the inhibition of colony forming efficiency (CFE) of B16 melanoma cells in vitro." | 3.68 | [Enhancement of the effects of anticancer agents on B16 melanoma cells by combination with cepharanthine--II. Antimetabolite, alkylating agent, nitrosourea]. ( Kubota, K; Kubota, R; Yamada, S, 1992) |
| "In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma." | 3.67 | Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma. ( Amato, DA; Ash, A; Borden, EC; Bruckner, H; Creech, RH; Cunningham, TJ; Falkson, G; Guerry, D; Savlov, ED, 1987) |
| "The effect of novobiocin on the formation of DNA replication intermediates in human melanoma cells was investigated." | 3.66 | Formation of a new DNA replication intermediate in novobiocin-treated human melanoma cells. ( Lönn, U, 1982) |
| "Ribonucleotide reductase activity and deoxyribonucleoside triphosphate (dNTP) pools were examined in several Syrian hamster melanoma cell mutants which are resistant to hydroxyurea (HU), an inhibitor of ribonucleotide reductase, and which also show increased resistance to bromdeoxyuridine (BrdU) mutagenesis." | 3.66 | Bromodeoxyuridine mutagenesis, ribonucleotide reductase activity, and deoxyribonucleotide pools in hydroxyurea-resistant mutants. ( Ashman, CR; Davidson, RL; Reddy, GP, 1981) |
| "Unscheduled DNA synthesis (UDS) indicated by melphalan was studied in freshly collected tumor cells from human melanoma metastases." | 3.66 | Different activities of unscheduled DNA synthesis in human melanoma and bone marrow cells. ( Hansson, J; Lewensohn, R; Ringborg, U, 1982) |
| "Mutant cell lines resistant to hydroxyurea (HU), an inhibitor of the enzyme ribonucleotide reductase, were selected from a line of Syrian hamster melanoma cells." | 3.66 | Resistance to bromodeoxyuridine mutagenesis and toxicity in mammalian cells selected for resistance to hydroxyurea. ( Davidson, RL; Kaufman, ER, 1979) |
| "A 43-year-old man with metastatic malignant melanoma was treated with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in combination with imidazole carboxamide and hydroxyurea." | 3.65 | Pulmonary fibrosis after prolonged therapy with 1,3-bis (2-chloroethyl)-1-nitrosourea. ( Crittenden, D; Haut, A; Tranum, BL, 1977) |
| "BCNU, hydroxyurea, and imidazole carboxamide (DTIC) were administered to 89 patients with disseminated malignant melanoma." | 3.65 | Combination chemotherapy for disseminated malignant melanoma. ( Coltman, CA; Costanzi, JJ; Delaney, FC; Hoogstraten, B; Quagliana, JM; Vaitkevicius, VK, 1975) |
| "Hydroxyurea is an S-phase specific drug." | 2.67 | Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial. ( Blumenreich, MS; Gentile, PS; Hamm, JT; Joseph, UG; Kellihan, MJ; Lalley, KA; Seeger, J; Sherrill, EJ; Sheth, SP; Sullivan, DM, 1993) |
| "Hydroxyurea (HU) is a ribonucleotide reductase inhibitor which blocks DNA excision-repair by the depletion of intracellular ribonucleotides." | 2.67 | A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. ( Carmichael, J; Ganesan, TA; Harris, AL; Philip, PA; Tonkin, K, 1994) |
| "Hydroxyurea (HU) is used to treat melanoma, and miRNA expression is altered after HU treatment in B16 melanoma cells." | 1.62 | Hydroxyurea regulates the development and survival of B16 Melanoma Cells by upregulating MiR-7013-3p. ( Gao, Y; Han, DX; Huang, YJ; Jiang, H; Wang, CJ; Wang, WH; Yuan, B; Zhang, JB; Zheng, Y, 2021) |
| " The thiolate-active site of RR from melanoma was inhibited by the new nitrosourea anti-tumour drug fotemustine (IC50 = 10(-4) M as determined from a dose-response study)." | 1.28 | Ribonucleotide diphosphate reductase from human metastatic melanoma. ( Elgren, TE; Hogenkamp, HP; MacFarlan, S; Nelson, LS; Schallreuter, KU; Yan-Sze, I, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 57 (78.08) | 18.7374 |
| 1990's | 10 (13.70) | 18.2507 |
| 2000's | 1 (1.37) | 29.6817 |
| 2010's | 4 (5.48) | 24.3611 |
| 2020's | 1 (1.37) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, YJ | 1 |
| Gao, Y | 1 |
| Wang, CJ | 1 |
| Han, DX | 1 |
| Zheng, Y | 1 |
| Wang, WH | 1 |
| Jiang, H | 1 |
| Yuan, B | 1 |
| Zhang, JB | 1 |
| Saito, A | 1 |
| Fujisawa, Y | 1 |
| Maruyama, H | 1 |
| Nakamura, Y | 1 |
| Ishitsuka, Y | 1 |
| Watanabe, R | 1 |
| Okiyama, N | 1 |
| Fujimoto, M | 1 |
| Oo, ZY | 1 |
| Proctor, M | 1 |
| Stevenson, AJ | 1 |
| Nazareth, D | 1 |
| Fernando, M | 1 |
| Daignault, SM | 1 |
| Lanagan, C | 1 |
| Walpole, S | 1 |
| Bonazzi, V | 1 |
| Škalamera, D | 1 |
| Snell, C | 1 |
| Haass, NK | 1 |
| Larsen, JE | 1 |
| Gabrielli, B | 1 |
| Jeong, YT | 1 |
| Cermak, L | 1 |
| Guijarro, MV | 1 |
| Hernando, E | 1 |
| Pagano, M | 1 |
| Ahmann, DL | 1 |
| Hahn, RG | 1 |
| Bisel, HF | 1 |
| Heinemann, L | 1 |
| Simpson, GR | 1 |
| Annels, NE | 1 |
| Vile, R | 1 |
| Melcher, A | 1 |
| Prestwich, R | 1 |
| Harrington, KJ | 1 |
| Pandha, HS | 1 |
| Krämer, OH | 1 |
| Knauer, SK | 1 |
| Zimmermann, D | 1 |
| Stauber, RH | 1 |
| Heinzel, T | 1 |
| Stehlin, JS | 1 |
| Hills, WJ | 1 |
| Rufino, C | 1 |
| Cassileth, PA | 1 |
| Hyman, GA | 1 |
| Lönn, U | 2 |
| Costanzi, JJ | 2 |
| Fletcher, WS | 2 |
| Balcerzak, SP | 2 |
| Taylor, S | 1 |
| Eyre, HJ | 1 |
| O'Bryan, RM | 2 |
| Al-Sarraf, M | 1 |
| Frank, J | 1 |
| Hill, GJ | 3 |
| Krementz, ET | 2 |
| Hill, HZ | 1 |
| Klemm-Mayer, H | 1 |
| Rasokat, H | 1 |
| Wagner, G | 1 |
| Ashman, CR | 2 |
| Reddy, GP | 1 |
| Davidson, RL | 3 |
| Lewensohn, R | 1 |
| Ringborg, U | 2 |
| Hansson, J | 1 |
| Sackett, LL | 1 |
| Haus, E | 1 |
| Lakatua, D | 1 |
| Swoyer, J | 1 |
| Lagerlöf, B | 1 |
| Lambert, B | 1 |
| Zietz, S | 1 |
| Lessin, S | 1 |
| Grattarola, M | 1 |
| Desaive, C | 1 |
| Nicolini, C | 1 |
| Knapp, DW | 1 |
| Chan, TC | 1 |
| Kuczek, T | 1 |
| Reagan, WJ | 1 |
| Park, B | 1 |
| Blumenreich, MS | 1 |
| Kellihan, MJ | 1 |
| Joseph, UG | 1 |
| Lalley, KA | 1 |
| Sherrill, EJ | 1 |
| Sullivan, DM | 1 |
| Hamm, JT | 1 |
| Gentile, PS | 1 |
| Sheth, SP | 1 |
| Seeger, J | 1 |
| Philip, PA | 3 |
| Carmichael, J | 2 |
| Tonkin, K | 2 |
| Ganesan, TA | 1 |
| Harris, AL | 3 |
| Kaklamanis, L | 1 |
| Morrison, H | 1 |
| Gatter, K | 1 |
| Eskenazi, AE | 1 |
| Powers, J | 1 |
| Pinkas, J | 1 |
| Oesterreich, S | 1 |
| Fuqua, SA | 1 |
| Frantz, CN | 1 |
| Souliotis, VL | 1 |
| Salisbury, A | 1 |
| Tates, AD | 1 |
| Mitchell, K | 1 |
| van Delft, JH | 1 |
| Ganesan, TS | 1 |
| Kyrtopoulos, SA | 1 |
| Ablett, E | 1 |
| Pedley, J | 1 |
| Dannoy, PA | 1 |
| Sturm, RA | 1 |
| Parsons, PG | 1 |
| Green, MD | 1 |
| MacKay, IR | 1 |
| Buckley, JC | 1 |
| Coates, AS | 1 |
| Paterson, AH | 1 |
| McPherson, TA | 2 |
| Willans, DJ | 1 |
| Honn, KV | 1 |
| Dunn, JR | 1 |
| Morgan, LR | 1 |
| Bienkowski, M | 1 |
| Marnett, LJ | 1 |
| Hartenstein, R | 1 |
| Ertl, E | 1 |
| Possinger, K | 1 |
| Ehrhart, H | 1 |
| Kaufman, ER | 2 |
| Hunter, JA | 1 |
| Aranha, GV | 1 |
| Grage, TB | 2 |
| Crittenden, D | 1 |
| Tranum, BL | 2 |
| Haut, A | 1 |
| Carter, RD | 1 |
| Metter, GE | 1 |
| Golomb, FM | 1 |
| Minton, JP | 1 |
| Sparks, FC | 1 |
| Delacrétaz, J | 1 |
| Vaitkevicius, VK | 1 |
| Quagliana, JM | 1 |
| Hoogstraten, B | 1 |
| Coltman, CA | 1 |
| Delaney, FC | 1 |
| Luce, JK | 2 |
| Schallreuter, KU | 1 |
| Elgren, TE | 1 |
| Nelson, LS | 1 |
| MacFarlan, S | 1 |
| Yan-Sze, I | 1 |
| Hogenkamp, HP | 1 |
| Kubota, R | 1 |
| Kubota, K | 1 |
| Yamada, S | 1 |
| Castel, T | 1 |
| Estapé, J | 1 |
| Viñolas, N | 1 |
| Mascaró, JM | 1 |
| Castro, J | 1 |
| Vilalta, A | 1 |
| Gratacós, R | 1 |
| Daniels, M | 1 |
| Palou, J | 1 |
| Grau, JJ | 1 |
| Hedley, D | 1 |
| Rugg, C | 1 |
| Musgrove, E | 1 |
| Taylor, I | 1 |
| Barnhill, RL | 1 |
| Wiles, JC | 1 |
| Retsas, S | 1 |
| Gershuny, AR | 1 |
| Abdi, EA | 1 |
| Hanson, J | 1 |
| Dixon, D | 1 |
| Quagliana, J | 1 |
| Neidhart, J | 1 |
| Costanzi, JH | 1 |
| Fabian, CJ | 1 |
| Neilan, B | 1 |
| Maloney, T | 1 |
| Amato, DA | 1 |
| Bruckner, H | 1 |
| Guerry, D | 1 |
| Ash, A | 1 |
| Falkson, G | 2 |
| Borden, EC | 1 |
| Creech, RH | 1 |
| Savlov, ED | 1 |
| Cunningham, TJ | 1 |
| Czarnetzki, BM | 1 |
| Aragon, V | 1 |
| Bröcker, EB | 1 |
| Krieg, V | 1 |
| Bünte, H | 1 |
| Macher, E | 1 |
| Wagenknecht, L | 2 |
| Kondi, ES | 1 |
| Gallitano, AL | 1 |
| Evjy, JT | 1 |
| Barnard, DR | 1 |
| McDonald, CJ | 1 |
| Johnson, FD | 1 |
| Jacobs, EM | 1 |
| Elford, HL | 1 |
| Laerum, OD | 1 |
| Grüneisen, A | 1 |
| Rajewsky, MF | 1 |
| Griswold, DP | 1 |
| Dykes, DJ | 1 |
| Kelley, CA | 1 |
| Roberts, BJ | 1 |
| Dominick, CA | 1 |
| Goldin, A | 1 |
| Carter, SK | 1 |
| Seiji, M | 1 |
| Takahashi, M | 1 |
| Laugier, P | 1 |
| Orusco, M | 1 |
| Jaccard, MA | 1 |
| Garin, AM | 1 |
| Lichinitser, MR | 1 |
| Moroz, LV | 1 |
| Ariel, IM | 1 |
| Hellmann, K | 1 |
| Paparopoli, G | 1 |
| Sciarrino, E | 1 |
| Slack, NM | 1 |
| Jones, R | 1 |
| Creasey, WA | 1 |
| Capizzi, RL | 1 |
| DeConti, RC | 1 |
| Larsen, RR | 1 |
| Gottlieb, JA | 1 |
| Frei, E | 1 |
| Sugiura, K | 1 |
| Lerner, HJ | 1 |
| Beckloff, GL | 1 |
| Godwin, MC | 1 |
| Willbanks, OL | 1 |
| Fogelmann, MJ | 1 |
| van Dyk, JJ | 1 |
4 reviews available for hydroxyurea and Malignant Melanoma
| Article | Year |
|---|---|
Cutaneous malignant melanoma.
Topics: Adult; Aged; Biopsy; Carmustine; Cyclophosphamide; Dactinomycin; Female; Humans; Hydroxyurea; Male; | 1976 |
Bromodeoxyuridine mutagenesis and deoxyribonucleotide pool imbalance in mammalian cells.
Topics: Animals; Base Composition; Bromodeoxyuridine; Cell Line; Cricetinae; Cytarabine; Deoxyadenosines; De | 1985 |
Rationale of combination chemotherapy based on preclinical experiments.
Topics: Animals; Antineoplastic Agents; Azaguanine; Carcinoma; Cytarabine; Drug Synergism; Humans; Hydroxyur | 1973 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Br | 1973 |
12 trials available for hydroxyurea and Malignant Melanoma
| Article | Year |
|---|---|
Clinical evaluation of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxam-ide (NSC-45388), melphalan (NSC-8806), and hydroxyurea (NSC-32065) in the treatment of disseminated malignant melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Dacarbazine; Female; Humans; | 1972 |
Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Dacarbazine; D | 1984 |
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1984 |
Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Adenoid Cystic; Colorectal Neoplasms; Drug Administration | 1993 |
A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dacarbazine; Female; Ga | 1994 |
Malignant melanoma (stage IIIB): a pilot study of adjuvant chemo-immunotherapy.
Topics: Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Carmustine; Clinical Trials as Topic; Dacarbazine; Fem | 1978 |
DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; | 1976 |
Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Combined Modality Therapy; | 1991 |
Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Humans | 1987 |
[Adjuvant chemotherapy in addition to radical surgical treatment of regional lymph node metastases in malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dacarbazine; | 1986 |
Single reversal trial of hydroxyurea (NSC-32065) in 91 patients with advanced cancer.
Topics: Anemia; Asparaginase; Azaserine; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Drug | 1970 |
Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065).
Topics: Adult; Aged; Blood Urea Nitrogen; Chondrosarcoma; Clinical Trials as Topic; Depression, Chemical; DN | 1970 |
57 other studies available for hydroxyurea and Malignant Melanoma
| Article | Year |
|---|---|
Hydroxyurea regulates the development and survival of B16 Melanoma Cells by upregulating MiR-7013-3p.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation; | 2021 |
Subungual melanoma complicated by hydroxyurea-induced melanonychia with non-melanoma Hutchinson's sign.
Topics: Aged; Female; Humans; Hydroxyurea; Hyperpigmentation; Melanoma; Nail Diseases; Nucleic Acid Synthesi | 2018 |
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, | 2019 |
FBH1 protects melanocytes from transformation and is deregulated in melanomas.
Topics: Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; DNA Breaks, Double-Stranded; DNA He | 2013 |
The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Disease Models, Animal; Fi | 2010 |
Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis.
Topics: Apoptosis; Caspase 3; Caspase Inhibitors; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhi | 2008 |
Disseminated melanoma. Biologic behavior and treatment.
Topics: Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Dactinomycin; Fluorouracil; Humans; Hydrazine | 1967 |
Treatment of malignant melanoma with hydroxyurea.
Topics: Adult; Aged; Female; Humans; Hydroxyurea; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Metastas | 1967 |
Formation of a new DNA replication intermediate in novobiocin-treated human melanoma cells.
Topics: Cells, Cultured; DNA; DNA Replication; DNA Topoisomerases, Type II; DNA, Neoplasm; Electrophoresis, | 1982 |
[Marked regression of melanoma metastases under combined chemotherapy].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female | 1984 |
Bromodeoxyuridine mutagenesis, ribonucleotide reductase activity, and deoxyribonucleotide pools in hydroxyurea-resistant mutants.
Topics: Animals; Bromodeoxyuridine; Cell Cycle; Cell Line; Cell Nucleus; Cricetinae; Deoxyribonucleotides; D | 1981 |
Different activities of unscheduled DNA synthesis in human melanoma and bone marrow cells.
Topics: Bone Marrow; Cell Line; DNA Repair; DNA Replication; DNA, Neoplasm; Female; Humans; Hydroxyurea; Mal | 1982 |
10 kb DNA replication intermediates are formed from Okazaki-fragments in human malignant melanoma cells.
Topics: Cell Cycle; Cells, Cultured; DNA; DNA Replication; DNA, Neoplasm; DNA, Single-Stranded; Humans; Hydr | 1982 |
Circadian host and tumor rhythms in Balb/C mice, rhythm induction in Harding-passey Melanoma.
Topics: Animals; Bone Marrow; Circadian Rhythm; Darkness; DNA Replication; Female; Hydroxyurea; Light; Melan | 1981 |
Normal UV-induced DNA repair synthesis in peripheral leukocytes from patients with malignant melanoma of the skin.
Topics: Aged; DNA Repair; Dose-Response Relationship, Radiation; Humans; Hydroxyurea; In Vitro Techniques; L | 1980 |
FPi analysis. II. Use of the method to monitor the in vivo kinetics of cell populations perturbed by hydroxyurea.
Topics: Animals; Bone Marrow; Cell Division; Hydroxyurea; Lung Neoplasms; Mathematics; Melanoma; Mice; Mice, | 1980 |
Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Carcinoma, Squamou | 1995 |
The influence of high dose hydroxyurea on the incorporation of 5-iodo-2-deoxyuridine (IUdR) by human bone marrow and tumour cells in vivo.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Biopsy, | 1993 |
Induction of heat shock protein 27 by hydroxyurea and its relationship to experimental metastasis.
Topics: Animals; Female; Gene Expression Regulation, Neoplastic; Heat Stress Disorders; Heat-Shock Proteins; | 1998 |
Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; DNA Adducts; DNA Repair; Female; Guanin | 1996 |
UVB-specific regulation of gene expression in human melanocytic cells: cell cycle effects and implication in the generation of melanoma.
Topics: Antineoplastic Agents; beta-Galactosidase; Cell Cycle; Cisplatin; Demecolcine; Genes, fos; Genes, p5 | 1998 |
The survival of patients with malignant melanoma receiving BCG with or without chemotherapy.
Topics: BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Immunity, Cellular; Melano | 1979 |
Inhibition of DNA synthesis in Harding-Passey melanoma cells by prostaglandins A1 and A2: comparison with chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; DNA Replication; DNA, Neoplasm; Doxo | 1979 |
[Influence of hydroxyurea on DNA synthesis of human bone marrow in vivo (author's transl)].
Topics: Adult; Bone Marrow; DNA; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Stomach Neoplasms; Testic | 1979 |
Resistance to bromodeoxyuridine mutagenesis and toxicity in mammalian cells selected for resistance to hydroxyurea.
Topics: Animals; Bromodeoxyuridine; Cell Line; Cricetinae; DNA; Drug Resistance; Hydroxyurea; Melanoma; Meso | 1979 |
Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
Topics: Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomu | 1977 |
Pulmonary fibrosis after prolonged therapy with 1,3-bis (2-chloroethyl)-1-nitrosourea.
Topics: Adult; Carmustine; Drug Therapy, Combination; Humans; Hydroxyurea; Imidazoles; Male; Melanoma; Pulmo | 1977 |
[Current aspects of melanoma].
Topics: Antigens, Neoplasm; B-Lymphocytes; Drug Therapy, Combination; Humans; Hydroxyurea; Imidazoles; Melan | 1976 |
Combination chemotherapy for disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Amides; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Therapy, C | 1975 |
Chemotherapy of melanoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; D | 1975 |
Ribonucleotide diphosphate reductase from human metastatic melanoma.
Topics: Antineoplastic Agents; Cell-Free System; Electron Spin Resonance Spectroscopy; Humans; Hydroxyurea; | 1992 |
[Enhancement of the effects of anticancer agents on B16 melanoma cells by combination with cepharanthine--II. Antimetabolite, alkylating agent, nitrosourea].
Topics: Alkaloids; Antineoplastic Agents; Benzylisoquinolines; Dacarbazine; Drug Synergism; Humans; Hydroxyu | 1992 |
Modulation of transferrin receptor expression by inhibitors of nucleic acid synthesis.
Topics: Animals; Cell Line; Cell Survival; Deferoxamine; DNA Replication; Flow Cytometry; Fluorescence; Huma | 1985 |
Malignant melanoma associated with multiple therapies for psoriasis.
Topics: Adrenal Cortex Hormones; Adult; Coal Tar; Humans; Hydroxyurea; Male; Melanoma; Methotrexate; Photoch | 1989 |
Central nervous system involvement in malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dexameth | 1988 |
Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carmustine; Com | 1987 |
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 1987 |
[Chemotherapy of malignant melanoma].
Topics: Alkylating Agents; Amides; Antineoplastic Agents; Bleomycin; Carmustine; Cyclohexanes; Drug Therapy, | 1973 |
Prolonged survival in a patient with hepatic malignant melanoma treated by intra-arterial bleomycin and oral hydroxyurea.
Topics: Administration, Oral; Angiography; Biopsy; Bleomycin; Catheterization; Choroid Neoplasms; Drug Thera | 1974 |
Cutaneous uses of the antiproliferative drugs.
Topics: Administration, Topical; Antimetabolites; Azauridine; Bleomycin; Chemical and Drug Induced Liver Inj | 1974 |
Chemotherapy of metastatic malignant melanoma. Experience with 73 patients.
Topics: Adult; Aged; Antineoplastic Agents; Chlorambucil; Colchicine; Cyclophosphamide; Cytarabine; Eye Neop | 1971 |
Effect of hydroxyurea on ribonucleotide reductase.
Topics: Animals; Carcinoma, Hepatocellular; Chemical Phenomena; Chemistry; Chick Embryo; Cytosine Nucleotide | 1968 |
Proliferative properties of malignant cell populations cultured in intraperitoneal diffusion chambers.
Topics: Animals; Cell Count; Cell Division; Cell Line; Cells, Cultured; Humans; Hydroxyurea; Leukemia, Myelo | 1973 |
Approaches to combination chemotherapy in rat, mouse, and hamster tumors.
Topics: Adenocarcinoma; Amides; Androstanols; Animals; Antineoplastic Agents; Cricetinae; Cyclohexanes; Cycl | 1974 |
Malignant melanoma with adjacent intraepidermal proliferation.
Topics: Adult; Chromomycin A3; Ethnicity; Female; Heel; Humans; Hydroxyurea; Lentigo; Lip Neoplasms; Lung Ne | 1974 |
[Polychemotherapy of metastatic melanoma. Preliminary report].
Topics: Adult; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Co | 1972 |
[Imidazole carboxamide in the treatment of disseminated melanoblastoma].
Topics: Amides; Carmustine; Humans; Hydroxyurea; Imidazoles; Lymphatic Metastasis; Melanoma; Neoplasm Metast | 1973 |
Anticancer therapy with hydrea: comparative study of daily vs. intermittent oral dosage.
Topics: Administration, Oral; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Dr | 1974 |
Investigational drugs for the treatment of malignant melanoma.
Topics: Alkylating Agents; Amides; Anorexia Nervosa; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; | 1974 |
[Recent diagnostic and therapeutic acquisitions in malignant melanoma].
Topics: Antineoplastic Agents; Camptothecin; Chloroquine; Colchicine; Humans; Hydroxyurea; Imidazoles; Immun | 1974 |
Improved systemic chemotherapy for malignant melanoma.
Topics: Adult; Aged; Amides; Antineoplastic Agents; Azo Compounds; Biopsy; Female; Humans; Hydroxyurea; Imid | 1971 |
Dose-schedule studies with hydroxyurea (NSC-32065) in malignant melanoma.
Topics: Administration, Oral; Adult; Amides; Female; Humans; Hydroxyurea; Imidazoles; Injections, Intravenou | 1971 |
Effect of 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962) and two related compounds on a spectrum of tumors.
Topics: Adenocarcinoma; Animals; Carcinoma, Ehrlich Tumor; Carcinoma, Krebs 2; Fibrosarcoma; Glioma; Hydroxy | 1967 |
Hydroxyurea (Hydrea).
Topics: Humans; Hydroxyurea; Leukemia, Myeloid; Leukocytes; Melanoma | 1968 |
Phase II study of hydroxyurea administered intermittently in malignant melanoma.
Topics: Adult; Aged; Chronic Disease; Female; Humans; Hydroxyurea; Leukocyte Count; Leukopenia; Male; Melano | 1970 |
Gastrointestinal melanosarcoma.
Topics: Adult; Aged; Biopsy; Colostomy; Female; Follow-Up Studies; Humans; Hydroxyurea; Intestinal Neoplasms | 1970 |
The chemotherapy of malignant melanoma.
Topics: Alkylating Agents; Amides; Antineoplastic Agents; Humans; Hydrazines; Hydroxyurea; Melanoma; Vinblas | 1968 |